Author Summary
SGLT2 Inhibitors May Lower Cardiac Risk from Cancer Therapy
Understanding Cancer Therapy-Related Cardiac Dysfunction Cancer therapy-related cardiac dysfunction (CTRCD) is an increasingly recognized consequence of many life-saving cancer treatments. Defined as a drop in left ventricular ejection fraction (LVEF) greater than 10%, often with […]
